`Tel: 571-272-7822
`
`
`
`
`Paper 16
`Entered: October 1, 2019
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_______________
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`NOVARTIS VACCINES AND DIAGNOSTICS, INC.,
`GRIFOLS WORLDWIDE OPERATIONS LIMITED,
`Patent Owner.
`_______________
`
`Case No. IPR2019-01086
`Patent 5,688,688
`_______________
`
`
`Before SHERIDAN K. SNEDDEN, CHRISTOPHER L. CRUMBLY, and
`ROBERT A. POLLOCK, Administrative Patent Judges.
`
`POLLOCK, Administrative Patent Judge.
`
`
`
`
`DECISION
`Dismissal Prior to Institution of Trial
`35 U.S.C. § 314
`
`
`
`
`
`
`
`
`
`
`
`IPR2019-01086
`Patent 5,688,688 B2
`
`
`On September 26, 2019, and pursuant to our authorization, Petitioner
`
`Regeneron Pharmaceuticals, Inc. filed a “Joint Motion to Terminate under
`
`35 U.S.C § 317(a) and 37 C.F.R. § 42.72” signed by counsel for both
`
`parties. Paper 15. The Motion requests that we “terminate this IPR
`
`proceeding in view of the District Court’s September 5, 2019 Judgment of
`
`Noninfringement and Order of Dismissal.” Id. at 2 (citing Ex. 1048, 3). The
`
`parties explain that in the copending litigation, Novartis Vaccines and
`
`Diagnostics, Inc., et al. v. Regeneron Pharmaceuticals, Inc., No. 18-cv-
`
`02434-DLC, the U.S. District Court for the Southern District of New York
`
`entered judgment of non-infringement for all claims of the ’688 Patent and
`
`dismissed the parties’ claims and counterclaims. Id. at 1–2 (citing Ex. 1048,
`
`1–2). In the Judgment of Noninfringement and Order of Dismissal, the
`
`District Court further stated that “Regeneron shall request to terminate” the
`
`instant Petition, and “[t]he parties shall cooperate as necessary to make any
`
`necessary filings with the Board in connection therewith.” Ex. 1048, 3.
`
`According to the parties, termination of this IPR proceeding is
`
`appropriate as it “will conserve Board resources.” Paper 15, 2–3. In
`
`addition, “[t]here is no settlement agreement to submit, and other than the
`
`District Court litigation mentioned above, there are no other pending cases
`
`or proceedings involving the ‘688 Patent that would be affected by the
`
`termination of this proceeding.” Id. at 3.
`
`This proceeding is in its initial stages and the Board has not yet
`
`decided the merits of the Petition. Because no inter partes review has been
`
`instituted, the termination Order sought in the Motion is not the most
`
`appropriate remedy. We instead construe Paper 15 as a joint request to
`
`dismiss the petition, which we find appropriate under the circumstances
`
`2
`
`
`
`IPR2019-01086
`Patent 5,688,688 B2
`
`before us. See 35 U.S.C. § 314; 37 C.F.R.
`
`§§ 42.5(a), 42.71(a).
`
`Accordingly, based on the foregoing, it is
`
`ORDERED that the Petition is dismissed;
`
`FURTHER ORDERED that no trial is instituted, and
`
`FURTHER ORDERED that this paper does not constitute a final
`
`written decision pursuant to 35 U.S.C. § 318(a).
`
`
`
`For PETITIONER:
`
`Irena Royzman
`Hannah Lee
`Kramer Levin Naftalis & Frankel LLP
`iroyzman@kramerlevin.com
`hlee@kramerlevin.com
`
`
`
`
`For PATENT OWNER:
`
`Deanne Mazzochi
`Paul Molino
`Matthew Anderson
`dmazzochi@rmmslegal.com
`paul@rmmslegal.com
`manderson@rmmslegal.com
`
`
`3
`
`